Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS . BICALUTAMIDE tablets, for oral use Initial U.S. Approval: 1995
Medication labelWhy this: Advisory · dailymed-prescription
Bicalutamide tablets, USP 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide tablets, USP 150 mg daily are not approved for use alone or with other treatments [see Clinical Studies (14.2)].
- generic_name
- bicalutamide
- product_names
- bicalutamide
- ndc
- 82804-082, 47335-485, 82804-082-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en